Pfizer will present 45 abstracts at ESMO 2026, including Phase 2 data for atirmociclib in breast cancer, Phase 3 results for sigvotatug vedotin in NSCLC, and updated Phase 2 data for tivunatamig in NSCLC. New analyses for PADCEV and TALZENNA will also be featured. The TALZENNA sNDA is under FDA Priority Review.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
